Cantargia receives patent approval in Japan and Mexico

Cantargia AB (“Cantargia”) has received approval in Japan and Mexico for its
patent application covering IL1RAP as a target molecule for antibody therapy and
leukemia diagnostics.
The protection covers treatment and diagnostics of leukemic cancer diseases, and
the approval means that Cantargia’s patent will be protected in Japan and Mexico
until 2030. Cantargia’s application is now protected in Europe, Japan, South
Africa, Mexico and Australia. The corresponding patent applications are being
examined by the relevant agencies in the US, China and other countries.
Cantargia also has two further patent families related to its CAN04 product
candidate.

“Japan is one of the largest markets for pharmaceuticals and this patent
approval is of great importance for Cantargia as well as for commercialization
of our product candidate CAN04. Mexico is a territory which in addition to its
size has a potential of strategic importance for commercialization in
neighboring markets. We have thus taken a further step to strengthen the
protection around our product candidate CAN04", CEO Göran Forsberg says.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com